Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Qiagen Plummeted Today

By Brian Orelli, PhD - Updated Oct 8, 2019 at 12:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A trio of news items has the healthcare company in transition.

What happened

Shares of Qiagen (QGEN -1.88%) are down 20% at 1:16 p.m. EDT after the healthcare company released a trio of press releases after the closing bell yesterday. There was some good news in the bunch, but it clearly didn't outweigh the bad.

So what

Let's get the bad news out of the way: Preliminary totals for the third quarter put revenue growth at about 3% at constant exchange rates, which is lower than the 4% to 5% that management had guided for. The company blamed slower sales in China and noted that sales were up 6% when excluding China sales.

On the bottom line, Qiagen still expects to earn $0.35 to $0.36 per share on an adjusted basis at constant exchange rates.

Qiagen also announced that CEO Peer Schatz is stepping down, although he'll stay on as a special advisor to help with the transition. Thierry Bernard, who heads Qiagen's molecular diagnostics business area, will serve as interim CEO while the company searches for a replacement.

Scientists working in a laboratory

Image source: Getty Images.

In the good-news category, Qiagen is teaming up with Illumina (ILMN -3.67%) in a 15-year partnership to develop diagnostic tests using NGS. Qiagen will develop the tests for Illumina's MiSeq Dx and NextSeq 550Dx systems and has the right to develop tests for future platforms Illumina brings to market. The companies will start with cancer tests, including companion diagnostics that doctors use to determine which drugs to give patients, but may move on to other fields such as cardiology, hereditary diseases, infectious diseases, inflammatory diseases, and autoimmune diseases.

It seems like a good move to partner with Illumina rather than try to beat it in the NGS space where Illumina is dominant, but the move will result in a charge of approximately $195 million to $200 million. Qiagen also announced restructuring plan that will add another $65 million in charges, putting the total charges in the $260 million to $265 million range, most of which will hit in the third quarter.

Now what

Qiagen is clearly in transition and the lack of permanent leadership at the top may slow the rebound. Today's 20% haircut is probably a bit excessive, but given the unknowns about the timing of the turnaround, it's understandable that healthcare investors who are buying now would want to factor in extra potential reward for taking on the unknown timing risk.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Illumina. The Motley Fool recommends Qiagen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

QIAGEN N.V. Stock Quote
QIAGEN N.V.
QGEN
$48.52 (-1.88%) $0.93
Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$214.80 (-3.67%) $-8.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.